PMID- 34724721
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20240404
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Print)
IS  - 2157-6564 (Linking)
VI  - 10 Suppl 2
IP  - Suppl 2
DP  - 2021 Nov
TI  - Optimizing allogeneic grafts in hematopoietic stem cell transplantation.
PG  - S41-S47
LID - 10.1002/sctm.20-0481 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used in 
      the treatment of hematological diseases. It is well known that allogeneic grafts 
      play a key role in predicting transplantation prognosis. Hematopoietic stem cells 
      (HSCs) are a functional part of grafts and are capable of reconstructing 
      hematopoiesis and immunity, but purified HSCs have not been identified or 
      isolated to date. In clinical practice, allogeneic grafts have been optimized to 
      improve transplantation outcomes. The optimized grafts are considered to engraft 
      successfully, reconstruct immunity rapidly, and exert a graft-vs-leukemia (GVL) 
      effect without causing severe graft-vs-host disease (GvHD). In the last several 
      decades, considerable efforts have been made in searching for optimized grafts 
      based on different graft manipulation approaches and different graft sources. 
      Currently, there is no uniform standard for optimized grafts in allogeneic 
      transplantation. In the future, sorting out the cellular elements responsible for 
      the effects of allo-HSCT might be a research direction for further optimization 
      of grafts. In this review, we propose the concept of optimized grafts and 
      summarize the recent advances made in the process of optimizing grafts.
CI  - (c) 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley 
      Periodicals LLC on behalf of AlphaMed Press.
FAU - Xu, Zheng-Li
AU  - Xu ZL
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AUID- ORCID: 0000-0002-2145-6643
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
SB  - IM
MH  - Allografts
MH  - *Graft vs Host Disease
MH  - Graft vs Leukemia Effect
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Transplantation, Homologous
PMC - PMC8560196
OTO - NOTNLM
OT  - CD34+
OT  - hematologic malignancies
OT  - hematopoiesis
OT  - hematopoietic stem cell transplantation
OT  - hematopoietic stem cells
COIS- The authors declared no potential conflicts of interest.
EDAT- 2021/11/02 06:00
MHDA- 2022/04/07 06:00
PMCR- 2021/11/01
CRDT- 2021/11/01 20:05
PHST- 2021/01/23 00:00 [revised]
PHST- 2020/10/26 00:00 [received]
PHST- 2021/03/04 00:00 [accepted]
PHST- 2021/11/01 20:05 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - SCT312938 [pii]
AID - 10.1002/sctm.20-0481 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2021 Nov;10 Suppl 2(Suppl 2):S41-S47. doi: 
      10.1002/sctm.20-0481.